CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Agios scraps sickle cell drug

Data ReadoutnegativeNegative
AI Analysis

Summary

Agios has discontinued development of its sickle cell disease drug following study failure, representing a setback in competition with Novo Nordisk and highlighting continued challenges in the sickle cell treatment landscape.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

Study failure

Importance:6/10
Sentiment:
-0.85
sickle cellclinical trial failuredrug discontinuationcompetitive setback
Related Companies

Read the original article

Published by BioPharma Dive on July 21, 2026 4:07 PM

Read Original